Israeli startup RedC Biotech is pioneering the large-scale production of lab-grown red blood cells derived from stem cells, aiming to address global blood shortages that cause millions of deaths annually. Founded by Dr. Ari Gargir, the company utilizes bioreactors to produce universal donor-type blood, circumventing the limits of human donation. Stem cells' ability to indefinitely divide under specific cues allows RedC to envision factories producing hundreds of transfusion units per vessel. The technology is progressing toward preclinical and clinical trials with eventual global manufacturing ambitions, highlighting a major step toward reliable emergency blood supply worldwide.